Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie will pay $250 million to acquire Celsius Therapeutics, a Cambridge, Massachusetts-based biotech that spun out of the Broad Institute to use single-cell…
AbbVie said on Thursday it had acquired privately held Celsius Therapeutics for about $250 million in cash, adding an experimental inflammatory bowel disease…
AbbVie has completed the acquisition of Celsius Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease, for approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired clinical-stage Celsius Therapeutics for $250M in cash, a deal announced and closed on June 27, 2024. Celsius's lead asset CEL383 is a potential first-in-class anti-TREM1 antibody for inflammatory bowel disease (IBD); TREM1 is expressed on inflammatory monocytes and neutrophils and acts as an amplifier of inflammation upstream of multiple known IBD pathways. At deal, CEL383 had completed a Phase 1 single-ascending-dose study in healthy volunteers. Under AbbVie the program was renamed ABBV-8736 and has advanced: a Phase 1 multiple-ascending-dose study (NCT07141199) completed, a Phase 1 subcutaneous-vs-intravenous bioavailability study (NCT07413133) began in February 2026, and ABBV-8736 was added as a treatment arm in AbbVie's Phase 2a platform study in moderate-to-severe Crohn's disease (NCT06548542). Top-25 pharma buyer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Celsius Therapeutics Inc. (this deal) | 2024 | $250M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Gastroenterology deals